Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anabolic-androgenic steroid use and erectile dysfunction.

The journal of sexual medicine·2026
Same author

Patients' Attitudes Towards Deprescribing and Associations With Patient-Related Factors Across Two Hospital Settings.

Basic & clinical pharmacology & toxicology·2026
Same author

A novel approach to stratifying patients for medication review in the emergency department using medications and routine blood tests.

British journal of clinical pharmacology·2026
Same author

Pharmacogenetic Predictors of Postoperative Opioid-Related Adverse Events: A Systematic Review.

Basic & clinical pharmacology & toxicology·2026
Same author

Healthcare Costs Associated With Anabolic Steroid Use: A Cohort Study.

Scandinavian journal of medicine & science in sports·2026
Same author

Efficacy of an interprofessional medication review among acutely admitted older medical patients: A randomized controlled trial.

British journal of clinical pharmacology·2025

Related Experiment Videos

[Quetiapine-induced leucopenia].

Elisabeth I Penninga1, Kim Peder Dalhoff, Signe E Lykkegaard

  • 1Klinisk Farmakologisk Enhed, Bispebjerg Hospital, DK-2400 København NV. ip08@bbh.hosp.dk

Ugeskrift for Laeger
|September 18, 2008
PubMed
Summary

Quetiapine, an antipsychotic, can cause asymptomatic cytopenia (low white blood cell and platelet counts) in schizophrenia patients. Discontinuation of quetiapine led to the resolution of leucopenia, highlighting a potential adverse effect.

Area of Science:

  • Pharmacology
  • Hematology
  • Psychiatry

Background:

  • Schizophrenia is a chronic mental disorder often treated with antipsychotic medications.
  • Quetiapine, a dibenzothiazepine antipsychotic, is widely prescribed for schizophrenia.
  • Monitoring blood counts is crucial during antipsychotic therapy.

Observation:

  • A 20-year-old male schizophrenia patient received quetiapine 900 mg daily.
  • Initial blood counts were normal upon admission.
  • Asymptomatic cytopenia, including leucopenia and thrombocytopenia, developed 15 weeks post-treatment initiation.

Findings:

  • Quetiapine treatment was associated with the development of leucopenia (2.2 billion/l) and thrombocytopenia (114 billion/l).
  • Leucopenia resolved within two weeks after discontinuing quetiapine.

Related Experiment Videos

  • The patient remained asymptomatic despite the cytopenia.

    • Implications:

    • Physicians should consider leucopenia as a potential adverse effect of quetiapine.
    • Awareness is critical, particularly in patients presenting with infection symptoms or pre-existing cytopenia.
    • Close hematological monitoring may be warranted in patients on high-dose quetiapine therapy.